Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Astellas Pharma
(OTCPK:ALPMF)
Intraday
$9.521
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$9.521
0
[0.00%]
Last update: 3:37PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Astellas Pharma Stock (OTC:ALPMF)
Astellas Pharma Stock (OTC: ALPMF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 17, 2023
Astellas Pharma And Pfizer Announced FDA Approval Of Supplemental Marketing Application For Xtandi (Enzalutamide) For Nonmetastatic Castration-sensitive Prostate Cancer With Biochemical Recurrence At High Risk For Metastasis
Benzinga Newsdesk
-
Nov 17, 2023, 3:52AM
Thursday, October 05, 2023
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Vandana Singh
-
Oct 5, 2023, 9:35AM
Friday, September 22, 2023
Why Is Seagen Stock Trading Higher Today?
Vandana Singh
-
Sep 22, 2023, 11:05AM
Wednesday, September 20, 2023
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
Vandana Singh
-
Sep 20, 2023, 2:12PM
Wednesday, August 23, 2023
Pfizer And Astellas Pharma Report FDA Grants Priority Review For XTANDI In Non-Metastatic Castration-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence
Benzinga Newsdesk
-
Aug 23, 2023, 6:47AM
Thursday, July 06, 2023
On July 6, At Special Meeting Iveric Bio Inc Board Of Directors Approved Merger Proposal With Astellas Pharma
Happy Mohamed
-
Jul 6, 2023, 1:07PM
Thursday, June 08, 2023
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Vandana Singh
-
Jun 8, 2023, 12:10PM
Tuesday, May 30, 2023
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
David Willey
-
Sponsored
Monday, May 15, 2023
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
Vandana Singh
-
May 15, 2023, 9:47AM
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
Vandana Singh
-
May 15, 2023, 6:57AM
Monday, May 01, 2023
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
Vandana Singh
-
May 1, 2023, 2:32PM
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Vandana Singh
-
May 1, 2023, 8:00AM
Tuesday, April 04, 2023
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Vandana Singh
-
Apr 4, 2023, 9:08AM
Tuesday, March 28, 2023
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Vandana Singh
-
Mar 28, 2023, 11:35AM
Monday, March 27, 2023
Japanese Government Urges China To Release Astellas Pharma's Employee
Vandana Singh
-
Mar 27, 2023, 7:34AM
Friday, March 17, 2023
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Vandana Singh
-
Mar 17, 2023, 10:17AM
Tuesday, January 31, 2023
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Vandana Singh
-
Jan 31, 2023, 1:15PM
Tuesday, January 24, 2023
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Vandana Singh
-
Jan 24, 2023, 10:58AM
Tuesday, October 25, 2022
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
Vandana Singh
-
Oct 25, 2022, 8:15AM
Thursday, August 18, 2022
Astellas' Menopause Drug Under FDA Review
Vandana Singh
-
Aug 18, 2022, 12:04PM
Tuesday, July 26, 2022
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Vandana Singh
-
Jul 26, 2022, 3:38PM
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Vandana Singh
-
Jul 26, 2022, 8:23AM
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Vandana Singh
-
Jul 26, 2022, 7:05AM
Tuesday, June 28, 2022
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Vandana Singh
-
Jun 28, 2022, 9:09AM
Sutro Biopharma Stock Surges On Cancer Treatment Pact
Vandana Singh
-
Jun 28, 2022, 7:25AM
Monday, June 27, 2022
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Vandana Singh
-
Jun 27, 2022, 10:50AM
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
Vandana Singh
-
Jun 27, 2022, 9:21AM
Monday, May 09, 2022
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
Vandana Singh
-
May 9, 2022, 1:57PM
Wednesday, April 13, 2022
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
Vandana Singh
-
Apr 13, 2022, 12:19PM
Tuesday, March 15, 2022
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
Vandana Singh
-
Mar 15, 2022, 3:43PM
Monday, March 07, 2022
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
Vandana Singh
-
Mar 7, 2022, 1:03PM
Tuesday, February 15, 2022
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
Vandana Singh
-
Feb 15, 2022, 7:40AM
Thursday, December 02, 2021
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Vandana Singh
-
Dec 2, 2021, 1:18PM
Monday, September 27, 2021
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Vandana Singh
-
Sep 27, 2021, 10:34AM
Tuesday, September 14, 2021
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Vandana Singh
-
Sep 14, 2021, 6:48AM
Wednesday, September 01, 2021
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Vandana Singh
-
Sep 1, 2021, 7:23AM
Friday, August 20, 2021
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Vandana Singh
-
Aug 20, 2021, 9:19AM
Wednesday, August 11, 2021
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
Vandana Singh
-
Aug 11, 2021, 8:06AM
Monday, July 19, 2021
Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data
Vandana Singh
-
Jul 19, 2021, 2:32PM
Monday, July 12, 2021
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
Vandana Singh
-
Jul 12, 2021, 6:48AM
Tuesday, May 11, 2021
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Vandana Singh
-
May 11, 2021, 12:32PM
Monday, May 03, 2021
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Vandana Singh
-
May 3, 2021, 2:48PM
Tuesday, April 27, 2021
Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold
Vandana Singh
-
Apr 27, 2021, 3:37PM
Wednesday, April 07, 2021
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
Vandana Singh
-
Apr 7, 2021, 5:54AM
Thursday, March 11, 2021
Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer
Vandana Singh
-
Mar 11, 2021, 8:21AM
Friday, February 19, 2021
Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies
Vandana Singh
-
Feb 19, 2021, 1:08PM
Thursday, February 18, 2021
Seagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings
Vandana Singh
-
Feb 18, 2021, 8:56AM
Tuesday, December 17, 2019
Stocks That Hit 52-Week Highs On Tuesday
Lisa Levin
-
Dec 17, 2019, 11:19AM
Monday, September 30, 2019
Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More
Shanthi Rexaline
-
Sep 30, 2019, 1:13PM
Friday, September 20, 2019
The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering
Shanthi Rexaline
-
Sep 20, 2019, 7:46AM
Show more